Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.In tests conducted by Quigley Pharma, mice treated with the company's investigational compound QR-442 had a delayed onset of multiple sclerosis and a considerable reduction in the severity of the disease.
Subscribe to our email newsletter
The anti-inflammatory effects of QR-442 were first evaluated in in-vitro experiments as well as in an immune-mediated inflammation model in mice.
In the mouse model, inflammation of the central nervous system is induced locally by a secondary immune response to an antigen, which is known scientifically as delayed type hypersensitivity (DTS), a process that is implicated in the pathology of multiple sclerosis.
“We are encouraged by these preliminary results. The data is sufficient to proceed with further studies which may lead to an IND submission to the FDA,” said Dr Richard Rosenbloom, COO of Quigley Pharma.
QR-442 was studied in a series of mouse experiments by Professor Yakov Ron, Department of Molecular Genetics and Microbiology and Immunology at the University of Medicine and Dentistry of New Jersey.
It is estimated that over 350,000 Americans live with multiple sclerosis and approximately 3 million live with it worldwide.